Annals of Behavioral Medicine

, Volume 40, Issue 2, pp 228–233 | Cite as

Lifestyle and Psychosocial Risk Factors Predict Non-adherence to Medication

Rapid Communication

Abstract

Blood pressure and cholesterol reduction have proven effective to reduce cardiovascular disease (CVD) risk, yet adherence to medical therapy is suboptimal and contributing factors to non-adherence are not well-established. The purpose of this study was to determine the prevalence and predictors of non-adherence to blood pressure and cholesterol-lowering medications in individuals who participated in an NHLBI-sponsored evaluation of a hospital-based screening and outreach program for high-risk employees and the community. This was a cross-sectional study of 371 adults (mean age 60 years, 57% female, 60% non-white) who were eligible to participate if they were men >40 years, women >50 years, or had established CVD or CVD-risk equivalent. Each participant received a comprehensive standardized CVD screening evaluation; medication non-adherence was defined as missing any pills for high blood pressure or abnormal cholesterol in the past week. Associations between participant demographics, lifestyle and psychosocial risk factors, and non-adherence were assessed using logistic regression to adjust for confounders. The prevalence of taking medication for high blood pressure or abnormal cholesterol in the study population was 48% and 38%, respectively. Among those participants, 14% reported missing high blood pressure pills and 23% reported missing cholesterol pills in the past week. Significant (p<0.05) univariate predictors of non-adherence to blood pressure medication were smoking, depression, feeling sad or blue for 2 weeks or more, and eating fast food ≥2 times per week. In a multivariable regression model adjusted for confounders, participants who reported missing any blood pressure pills in the past week were 6.6 times more likely to have uncontrolled hypertension (≥140/90 mmHg) compared to those who were adherent (95% CI = 2.1-20.2). Age <65 years and eating outside the home ≥2 times per week were significantly associated with non-adherence to cholesterol medication even after adjusting for measured confounders. Non-adherence to preventive medications was associated with poor blood pressure control and several lifestyle and psychosocial risk factors for CVD. This information may be clinically useful to help identify individuals who may be non-adherent to medical therapy and at increased CVD risk.

Keywords

Cardiovascular disease Depression Prevention Risk factors Adherence 

References

  1. 1.
    Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States. JAMA. 2003;290:199–206.CrossRefPubMedGoogle Scholar
  2. 2.
    American Heart Association. Heart disease and stroke statistics—2009 update. Dallas, Texas: American Heart Association; 2009.Google Scholar
  3. 3.
    Krousel-Wood M, Thomas S, Muntner P, Morisky D. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol. 2004;19:357–362.CrossRefPubMedGoogle Scholar
  4. 4.
    Winickoff RN, Murphy PK. The persistent problem of poor blood pressure control. Arch Intern Med. 1987;147:1393–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European Countries, Canada, and the United States. Hypertension. 2004;43:10–17.CrossRefPubMedGoogle Scholar
  6. 6.
    Ansell BJ. Not getting to goal: the clinical costs of noncompliance. J Manag Care Pharm. 2008 14(6 Suppl B):9–15.Google Scholar
  7. 7.
    Ockene IS, Hayman LL, Pasternak RC, Schron E, Dunbar-Jacob J. Task force #4—adherence issues and behavior changes: achieving a long-term solution. 33rd Bethesda Conference. J Am Coll Cardiol. 2002;40(4):630–40.CrossRefPubMedGoogle Scholar
  8. 8.
    Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks: US population data. Arch Intern Med. 1993;153:598–615.CrossRefPubMedGoogle Scholar
  9. 9.
    Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Final Report. Circulation. 2002;106:3143–3421.Google Scholar
  10. 10.
    Borzecki AM, Oliveria SA, Berkowitz DR. Barriers to hypertension control. Am Heart J. 2005;149:785–794.CrossRefPubMedGoogle Scholar
  11. 11.
    Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–97.CrossRefPubMedGoogle Scholar
  12. 12.
    Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455–61.CrossRefPubMedGoogle Scholar
  13. 13.
    Erickson SR, Williams BC, Gruppen LD. Relationship between symptoms and health-related quality of life in patients treated for hypertension. Pharmacotherapy. 2004;24:344–350.CrossRefPubMedGoogle Scholar
  14. 14.
    Stilley CS, Sereika S, Muldoon MF, Ryan CM, Dunbar-Jacob J. Psychological and cognitive function: predictors of adherence with cholesterol lowering treatment. Ann Behav Med. 2004;27(2):117–24.CrossRefPubMedGoogle Scholar
  15. 15.
    Pickering TG, Hall JE, Appel LJ, et al. Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Recommendations for blood pressure measurement in humans and experimental animals: part 1. Hypertension. 2005;45(1):142–161.PubMedGoogle Scholar
  16. 16.
    Parikh P, Mochari H, Mosca L. Clinical utility of a fingerstick technology to identify individuals with abnormal blood lipids and high-sensitivity C-reactive protein levels. Am J Health Promot. 2009;23(4):279–82.CrossRefPubMedGoogle Scholar
  17. 17.
    Bard RL, Kaminsky LA, Whaley MH, Zajakowski S. Evaluation of lipid profile measurements obtained from the cholestech L.D.X. analyzer. J Cardiopulm Rehab. 1997; 17: 413–418.Google Scholar
  18. 18.
    Mosca L, Edelman D, Mochari H, Christian AH, Paultre F, Pollin I. Waist circumference predicts cardiometabolic and global Framingham risk among women screened during National Woman’s Heart Day. J Women’s Health (Larchmt). 2006;15(1):24–34.CrossRefGoogle Scholar
  19. 19.
    Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA. 2003;289:2560–2572. Erratum in: JAMA. 2003;290:197.Google Scholar
  20. 20.
    Rosengren A, Hawken S, Ounpuu S, et al. INTERHEART investigators. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):953–62.CrossRefPubMedGoogle Scholar
  21. 21.
    Morris AB, Li J, Kroenke K, Bruner-England TE, Young JM, Murray MD. Factors associated with drug adherence and blood pressure control in patients with hypertension. Pharmacotherapy. 2006;26(4):483–92.CrossRefPubMedGoogle Scholar
  22. 22.
    Carmody TP, Fey SG, Pierce DK, Connor WE, Matarazzo JD. Behavioral treatment of hyperlipidemia: Techniques, results, and future directions. J Behav Med. 1982;5(1):91–116.CrossRefPubMedGoogle Scholar
  23. 23.
    Goldenberg N, Glueck C. Efficacy, effectiveness and real life goal attainment of statins in managing cardiovascular risk. Vasc Health Risk Manag. 2009;5(1):369–76.PubMedGoogle Scholar
  24. 24.
    Walker EA, Molitch M, Kramer MK. Adherence to preventive medications: predictors and outcomes in the diabetes prevention program. Diabetes Care. 2006;29(9):1997–2003.CrossRefPubMedGoogle Scholar
  25. 25.
    Mochari H, Ferris A, Adigopula S, Henry G, Mosca L. Cardiovascular disease knowledge, medication adherence, and barriers to preventive action in a minority population. Prev Cardiol. 2007;10(4):190–5.CrossRefPubMedGoogle Scholar
  26. 26.
    Mann DM, Allegrante JP, Natarajan S, Halm EA, Charlson M. Predictors of adherence to statins for primary prevention. Cardiovasc Drugs Ther. 2007;21(4):311–6.CrossRefPubMedGoogle Scholar
  27. 27.
    Hendrix KH, Riehle JE, Egan BM. Ethnic, gender, and age-related differences in treatment and control of dyslipidemia in hypertensive patients. Ethn Dis. 2005;15(1):11–6.PubMedGoogle Scholar
  28. 28.
    Hansen RA, Kim MM, Song L, Tu W, Wu J, Murray MD. Comparison of methods to assess medication adherence and classify nonadherence. Ann Pharmacother. 2009;43(3):413–22.CrossRefPubMedGoogle Scholar

Copyright information

© The Society of Behavioral Medicine 2010

Authors and Affiliations

  1. 1.Columbia University Medical CenterNew YorkUSA
  2. 2.Preventive Cardiology ProgramNewYork Presbyterian HospitalNew YorkUSA

Personalised recommendations